Bcl-2 inhibitor combo for advanced HR+ breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new Bcl-2 inhibitor (BGB-21447) combined with other therapies for advanced HR+/HER2- breast cancer that has already been treated with hormone therapy and a CDK4/6 inhibitor. It aims to see if these combinations are safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your breast cancer must be HR-positive and HER2-negative (a common type).
- You must have had at least one prior treatment for advanced cancer, including hormone therapy and a CDK4/6 inhibitor.
- You must not have taken a Bcl-2 inhibitor before.
- You must have no uncontrolled or untreated cancer spread to the brain or spinal cord lining.
- You must be able to get around and take care of yourself (ECOG status 0 or 1).
- If you are a woman who can still have children, you must use effective birth control during the study and for a period after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called BGB-43395 alone or with other treatments for advanced solid tumors, especially breast cancer. The goal is to find the best dose and see how well it works. It may be an option if your cancer has not responded to other treatments.
This Phase 1/2 study tests how well a new treatment combination (VS-6766, abemaciclib, and fulvestrant) works for metastatic or hard-to-remove breast cancer that is hormone-driven (ER/PR positive) and HER2 negative. It is mainly designed to find the safest dose and then see whether it can control the cancer after it has progressed on certain prior medicines.
This trial tests a new combination of drugs for advanced breast cancer that is both hormone receptor-positive (HR+) and HER2-positive. The treatment combines fulvestaciclib (a CDK4/6 inhibitor) with anti-HER2 therapy and endocrine therapy, aiming to slow or stop cancer growth. It may be an option if you have not yet had treatment for advanced disease.
This trial tests whether combining three medicines can better control hormone-receptor–positive, HER2-negative metastatic breast cancer that cannot be cured with surgery or radiation. It may help shrink tumors and slow disease growth compared with standard hormone therapy approaches.
This trial tests a new combination of two targeted medicines for people with a certain type of advanced breast cancer that has grown despite hormone therapy. The medicines may help shrink tumors and slow the cancer's growth.
This trial tests a new drug (GDC-4198) combined with standard hormone therapies for people with advanced or metastatic breast cancer that is hormone receptor-positive and HER2-negative. It may help by improving the effectiveness of hormone therapy and slowing cancer growth.
Hear when a new Hormone-receptor-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.